HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: HER2-low breast cancer shows a lower immune response compared to HER2-negative cases ; volume:12 ; number:1 ; day:28 ; month:7 ; year:2022 ; pages:1-10 ; date:12.2022
Scientific reports ; 12, Heft 1 (28.7.2022), 1-10, 12.2022

Creator: Ende, Nadine S. van den
Smid, Marcel
Timmermans, Annemieke
Brakel, Johannes B. van
Hansum, Tim
Foekens, Renée
Trapman, Anita M. A. C.
Heemskerk-Gerritsen, Bernadette A. M.
Jager, Agnes
Martens, John W. M.
Deurzen, Carolien H. M. van

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-022-16898-6

URN: urn:nbn:de:101:1-2022102312533626991518

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:23 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ende, Nadine S. van den
Smid, Marcel
Timmermans, Annemieke
Brakel, Johannes B. van
Hansum, Tim
Foekens, Renée
Trapman, Anita M. A. C.
Heemskerk-Gerritsen, Bernadette A. M.
Jager, Agnes
Martens, John W. M.
Deurzen, Carolien H. M. van
SpringerLink (Online service)

Other Objects (12)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow

Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer

EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial

Use of Taxanes in Metastatic HER2-negative Breast Cancer – a Status Report

Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

Related objects

Reset password